Visions of 2020

This last week was actually a very good week for the Tailwinds' portfolio. Despite the overall quiet of a holiday week (or maybe because of it?), led by a 22% gain in Provention Bio, we managed to put up...
Tailwinds' Take: needed financing to keep things going until they can land a strategic investor. The clock is ticking on my ability to hold this any longer. I'm expecting a bounce in early 2020 and, if they don't close...
The market seems took a little hit this week, then bounced back. The net result of which was the wind coming out of the recent micro-cap rally. This is likely a temporary setback as valuations remain much cheaper and...
Tailwinds' Take: the science behind XB3™ appears to be very interesting to the medical community. Hopefully this translates into some strategic partnerships soon. GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform...
Those who know me well are well aware that Wednesdays are my favorite night of the week. That's the night I go out mountain biking with The Gestalt Haus Gang, ending up at a similarly-named (mountain) biker bar tipping...
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system...
On Friday, my favorite little boom or bust biotech, Bioasis, reported their results. There is very little to learn from looking at the numbers; this is a tiny, pre-revenue company. However, in the MD&A section of the filing was...
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas...
Tailwinds' Take: Nice to see this patent as it shows they continue to make progress behind the scenes, despite their noticeable lack of marketing around the company and its shares.  Guilford, CT. Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI), (the “Company” or...
I’ve held off on my August recap much like a war veteran will refrain from telling tales from the trenches. Not that my experiences are nearly as terrible as a real war, but in the figurative sense, August left...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.